Drug trial aims to stop lung cancer before it starts
NCT ID NCT03347838
Summary
This study is testing whether the drug nivolumab can help the body's immune system recognize and clear abnormal, pre-cancerous cells in the lungs of high-risk current and former smokers. Participants receive four doses of the drug over eight weeks and undergo lung exams to see if the abnormal cells improve. The goal is to see if this approach can prevent these pre-cancerous changes from developing into full lung cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOBACCO SMOKING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Denver VA Hospital
Denver, Colorado, 80220, United States
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.